Mounjaro is FDA-approved specifically for type 2 diabetes, but it is not used exclusively by people with diabetes. The same active ingredient, tirzepatide, is sold under a separate brand name called Zepbound for weight loss in people without diabetes. Doctors can also prescribe Mounjaro itself off-label for weight management, though insurance coverage in that scenario is limited.
What Mounjaro Is Approved For
The FDA approved Mounjaro in 2022 as an add-on to diet and exercise for improving blood sugar control in adults with type 2 diabetes. That is its only official indication. The labeling explicitly states it is not intended for people with type 1 diabetes, which is a different condition involving autoimmune destruction of insulin-producing cells.
Mounjaro works by activating two hormone receptors that play a role in blood sugar regulation and appetite. One of these hormones helps your body release insulin more effectively after meals, while the other improves insulin sensitivity through a mechanism that appears to be independent of weight loss. Together, they lower blood sugar while also significantly reducing hunger, which is why the drug caught attention for weight management early on.
The Same Drug Exists for Weight Loss
Eli Lilly, the company behind Mounjaro, launched a second brand called Zepbound containing the exact same molecule: tirzepatide. The two products are molecularly identical. Zepbound is FDA-approved for chronic weight management in adults with obesity (BMI of 30 or higher) or those with a BMI of 27 or higher who have at least one weight-related health condition. Zepbound also has an approval for obstructive sleep apnea.
The dual branding exists for practical reasons. Separate brand names allow for different insurance coverage pathways, different prescribing contexts, and compliance with FDA labeling rules. If your doctor wants to prescribe tirzepatide for weight loss rather than diabetes, they would typically write the prescription for Zepbound. Some doctors do prescribe Mounjaro off-label for weight loss, but this creates complications with insurance that we’ll get to below.
Weight Loss Results in People Without Diabetes
The evidence for tirzepatide as a weight loss drug comes largely from the SURMOUNT-1 trial, a large phase 3 study that enrolled overweight or obese adults who did not have diabetes. Over 72 weeks, participants on the highest dose lost an average of 20.9% of their body weight, compared to 3.1% in the placebo group. The middle dose produced 19.5% loss, and the lowest therapeutic dose produced 15%. For someone weighing 250 pounds, the highest dose translates to roughly 52 pounds lost over about a year and a half.
These are some of the largest weight reductions ever seen in a pharmaceutical trial, and they established tirzepatide as a serious option for obesity treatment regardless of diabetes status.
How the Drug Works in Your Body
Tirzepatide mimics two gut hormones your body naturally releases after eating. The first, GLP-1, slows stomach emptying, reduces appetite, and triggers insulin release when blood sugar is elevated. The second, GIP, improves how sensitive your tissues are to insulin and acts on fat tissue and appetite centers in the brain. Research has shown that an intact GIP signaling pathway in the brain is necessary to achieve the full appetite-suppressing effect of the drug.
This dual action is what separates Mounjaro from older GLP-1 drugs like semaglutide (Ozempic/Wegovy), which only target the GLP-1 receptor. The combination appears to produce stronger effects on both blood sugar and body weight.
Insurance Coverage Depends on the Diagnosis
Here’s where the practical distinction matters most. Insurance plans, including Medicare, generally cover Mounjaro when it’s prescribed for type 2 diabetes. Coverage for weight loss alone is much less common and often explicitly excluded under Mounjaro’s brand name. If you don’t have a type 2 diabetes diagnosis, your insurer will typically expect a Zepbound prescription instead, and even then, many plans don’t cover weight loss medications.
Even with a diabetes diagnosis, you may face prior authorization requirements, step therapy (meaning your insurer wants you to try a cheaper medication first), dose limits, or higher copays if Mounjaro sits on a non-preferred tier. Medicare does not currently cover any GLP-1 based medications prescribed solely for weight loss, because federal law still generally excludes obesity-only drugs from Part D coverage. Medicaid coverage varies by state, and several states have placed new limits on GLP-1 medications for obesity due to budget pressures.
Without insurance, tirzepatide can cost over $1,000 per month regardless of which brand name is on the box.
Starting and Adjusting the Dose
Whether prescribed for diabetes or weight loss, tirzepatide follows the same titration schedule. You start with a 2.5 mg injection once per week for the first four weeks. This starting dose is not considered therapeutic for blood sugar control; it exists to let your body adjust and minimize side effects, particularly nausea. After four weeks, the dose increases to 5 mg weekly. From there, your doctor can raise it by 2.5 mg increments every four weeks or longer, up to a maximum of 15 mg per week, depending on your response and tolerance.
Who Should Not Take It
Mounjaro carries a boxed warning about thyroid tumors. In rat studies, tirzepatide caused thyroid C-cell tumors at doses comparable to what humans receive. Whether this translates to a real risk in people is unknown, but as a precaution, the drug is contraindicated if you have a personal or family history of medullary thyroid carcinoma or a condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). It’s also contraindicated if you’ve had a serious allergic reaction to tirzepatide or any inactive ingredient in the formulation.
An observational study published in JACC: Advances found that among adults with type 2 diabetes and pre-existing heart disease, tirzepatide was associated with a 40% lower rate of heart attack, stroke, and death compared to older GLP-1 drugs. Larger trials powered specifically to measure cardiovascular outcomes are still underway, but early signals suggest the drug is at minimum safe for the heart and possibly protective.